Fresh feces from 25 patients were homogenized and incubated with labeled cholic or chenodeoxycholic acid. After 24 hours of incubation, the percent change to the 7a-dehydroxylated form was measured. In 11 patients, the oral administration of 2g of neomycin daily significantly reduced the levels of serum cholesterol (from an average of 316 mg/100 ml plasma to 237 mg/100 ml plasma) and markedly inhibited the extent of 7a-dehydroxylation of cholic acid (from 89% to 9%); in 2 patients whose serum cholesterol levels were not lowered, the degradation of cholic acid remained unchanged (control 93%, neomycin 91%). In 5 patients the administration of kanamycin reduced serum cholesterol levels (from 280 mg/100 ml plasma to 252 mg/100 ml plasma) and also inhibited 7a-dehydroxylation of cholic acid (from 92% to 21%); in 3 additional patients this drug failed to lower serum cholesterol concentrations and had no effect on bile acid degradation (control 91%, kanamycin 92%). Similar results were obtained with chloramphenicol in 3 patients, and equivocal results were obtained with chlortetracyeline in 3 patients. The correlation coefficient between undegraded cholic acid and percent decrease in serum cholesterol concentrations (r = 0.732) was statistically significant ( P < 0.001). It is proposed that serum cholesterol levels might be controlled in part by the prevalence of bile acid-degrading bacteria within the gastrointestinal tract.
• Oral administration of small doses of neomycin sulfate (2 g or less daily) lowers the concentration of serum cholesterol in man (1) (2) (3) (4) (5) (6) (7) and reduces the size of body pools of cholesterol (7) . Of 18 different antibacterial drugs studied to date (2) (3) (4) (5) (6) , neomycin, kanamycin (3), paromomycin (4), chlortetracyeline (3), and para-aminosalicylic acid (2, 3) have all been shown to reduce serum cholesterol concentrations in man but only when they are administered orally.
The mechanism by which neomycin or other antibacterial drugs cause these changes in serum cholesterol concentration has not been defined. The effect of the drug at a daily dose of 2 g is independent of dietary intake of fat or cholesterol, and fecal fat excretion is not increased (6) , although with larger doses (6-12 g/day) steatorrhea is commonly observed (8) . However, the reduction of serum cholesterol levels during the oral administration of neomycin occurs concomitantly with an increase in the fecal excretion of bile acids and neutral steroids (9, 10) .
Several groups of workers have attempted to specify the mechanism by which fecal steroid excretion is increased. The in vitro addition of neomycin to solutions of bile acids (11) or to human bile (12) results in the selective precipitation of bile acids; the degree of precipitation depends on conjugation, number of hydroxyl groups, pH of the solution, etc. (13) . Oral administration of neomycin interferes with the in vivo bacterial conversion of cholic acid to deoxycholic acid in man (9, 14) and with the formation
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of deoxycholic and allodeoxycholic acids in rabbit (15) . In one clinical study (16) the administration of neomycin resulted in in vivo precipitation of fatty acids, cholesterol, and bile acids from mixed micellar solutions; however, in another study (14) the duodenal micellar bile salt and fatty acid concentrations were not significantly altered. Also, during the administration of neomycin the size of bile acid pools diminished in these patients, and turnover rates of cholic acid increased in some (14) . Thus, the evidence about the physical effects of neomycin within the intestinal lumen appears to be contradictory, yet it seems to be established that the drug increases the fecal excretion of cholesterol end products and possibly alters the turnover rates and pool sizes of bile acids.
We have proposed (2) (3) (4) (5) (6) that the effect of neomycin and possibly of the other cholesterollowering antibacterial drugs may depend on their action on the intestinal bacterial flora. As a corollary, it seems possible that in comparing populations of different geographic areas the effect of environmental factors on the character of the microbial flora of the intestine may be one of the important factors influencing serum cholesterol levels and the size and turnover of body pools of cholesterol. In the present study the possibility that the intestinal flora exerts this influence by controlling the extent of the intraluminal bacterial degradation of primary to secondary bile acids was considered. The relationship of serum cholesterol levels to the in vitro degradation of primary bile acids by the fecal bacterial flora was studied along with the effect of neomycin and other antibacterial drugs on these variables. An in vitro assay of the capacity of human feces to cause 7a-dehydroxylation of the primary bile acids of man (cholic and chenodeoxycholic acids) was developed and applied in tests on feces of patients that received cholesterol-lowering antibiotics. Excellent correlation was shown between the extents of in vivo lowering of serum cholesterol and in vitro 7a-dehydroxylation.
Methods

PATIENTS
Twenty-five volunteer patients were studied in 36 experiments. The age and sex of the patients are included in Tables 1-3 . All patients were ambulatory. Routine medications, if any, were kept constant during the experimental periods. Substances other than the experimental drugs known to influence sterol metabolism or serum cholesterol levels were not given. The diet was uncontrolled, but the patients were instructed to adhere to their customary diets.
Several patients were repeatedly studied in several experiments. A minimum of 6 weeks elapsed after the termination of the previous experimental period before a patient was restudied using another drug. Five patients in the neomycin group (nos. 1, 7, 8, 9, and 11) were used in other experiments, e.g., patient 1 responded to neomycin but failed to respond to kanamycin.
EXPERIMENTAL DESIGN
A fresh (less than 8 hours old) stool sample was collected twice weekly from each patient during the 2-week control period. A blood sample was taken in the fasting state on the days of stool collection. At the end of the control periods the patients were given the experimental medication for 2 additional weeks, and the collection of stool and blood samples was continued twice weekly as described below. In 24 of the 36 experiments, four samples were collected during control periods and four during the administration of the experimental medications. In the remaining 12 experiments, there was a slight deviation in this collection procedure; for example, four samples were collected during control and five samples during experimental periods, or three samples were collected during control and four during experimental periods. The overall average number of specimens obtained during control periods was 3.76 and the average collected during experimental periods was 3.92 in the 36 experiments.
Physical examinations, complete blood counts, urinalysis, blood urea nitrogen, blood sugar, serum billirubin, serum glutamic oxalacetic transaminase, and cephalin flocculation were carried out at the beginning and the end of the experiments. The level of total serum cholesterol was determined bv the method of Abell et al. (17) . Serum triglyceride levels were measured by the method of Van Handel et al. (18) .
STANDARD ASSAY
Human stools of a complete bowel movement were weighed and homogenized in a blender with sterile distilled water. A sample of 5 g of the homogenate was dried in a boiling steam bath under gentle air flow. The dry residue was weighed and the dry weight of stool per gram of homogenate was calculated. A second sample of stool homofienate equivalent to 200 mg of dry stool was added to 30 ml of sterile medium (19) . 24-lc1 C-Cholic acid (49 mc/mM), or C-chenodeoxycholic acid (32 mc/mM), purified by thin-layer chromatography (isooctane-isopropyl alcohol-acetic acid soluHon, 120:40:1) and suspended in H a O, was added to the medium-stool mixture. The usual amount of tracer added was 2-3 x 10 5 dpm/incubate. Nitrogen was bubbled through the mixture for 1 minute (2 liters/min), and the mixture was incubated at 37-38°C for 0.5-24 hours.
At the end of incubation 5 ml of 33$ KOH and 60 ml of warm ethanol were added to the incubates. The sample was cooled in a 4°C refrigerator and was then centrifuged. The sed'ment was washed with 5 ml of methanol. The supernatant fluid was transferred and evaporated to reduce the volume to about 30 ml. The mixture was cooled in an ice bath and acidified to pH 2 (Congo Red) by the drop-by-drop addition of a 6N
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HC1 solution. The 5 ml of methanol from the backwash of the sediment was added to the cold mixture, and bile acids were extracted three times with equal volumes of peroxide-free ethyl ether. The ether extracts were pooled, washed with water until neutral, and evaporated to a volume of 15 ml. The ether extract was plated on 20 x 20-cm thin-layer chromatography plates (silica-gel G) together with known bile acid standards. The plates were developed with a solvent system of isooctaneisopropyl alcohol-acetic acid (120:40:1). The spots were visualized by a spray of 10% phosphomolybdic acid. Each spot corresponding to a specific bile acid was quantitatively transferred into liquid scintillation counter vials, 4 ml of methanol was added, and the vials were heated to 50°C for 30 minutes. After cooling, radioactivity was measured, and quenching was monitored by an external source of radioactivity.
VALIDATION OF THE ASSAY
Quantitative Recovery.-In each experiment the entire surface of the thin-layer chromatography plates was scraped, and the gel was introduced into one of the liquid scintillation counter vials. The area on the plates which was above deoxycholic or lithocholic acid (including the solvent front) contained no measurable radioactivity in any of the experiments. The recovery of radioactivity was 93.2-99.0% (average 95.0%). There were only traces of label left in the final water-methanol layer after three extractions, and a fourth ether extract contained no measurable amounts of label.
Material recovered from the identified thin-layer chromatography spots was analyzed by gas-liquid chromatography (1% Hi Eff 8-BP column). The material obtained from the thin-layer chromatography spots corresponding to cholic acid yielded a single gasliquid chromatography peak with the retention time of cholate. The material recovered from the thin-layer chromatography spots corresponding to deoxycholic acid yielded a major peak with the gas-liquid chromatography retention time of deoxycholate. Immediately preceding this peak there was a small unidentified peak that had the gas-liquid chromatography retention time of isodeoxycholate.
In control stool samples, an average of about 3-15% of the radioactivity remained at the origin or migrated to different positions not corresponding to cholic, deoxycholic, chenodeoxycholic, or lithocholic acids in the thin-layer chromatography system used. These labeled compounds were present only in trace amounts; although they are presumably bile acids, they were not further identified.
Reproducibility.-The procedure was highly reproducible. In ten parallel incubates of the same stool homogenate the average distribution of radioactivity was 1.3 ±0.17% (SE) (cholic acid) and 97.8 ±0.10% (deoxycholic acid).
Time-Course, Cas Phase, and pH.-The time curve of the rate of conversion of cholic acid into deoxycholic acid is shown in Figure 1 . About 90% or more of the added ]j| C-cholic acid was degraded by the fecal flora of a normal control subject after a 4-6-hour incubation under these experimental conditions. The cholic acid curve remained at this lower plateau for the rest of the 
Time-kinetic curves for the degradation of "iC-cholic acid (solid line) and its conversion to deoxycholic acid (broken tine). Incubated stool homogenates were equivalent to 200 mg of dry weight.
experiment. A similar curve was obtained for chenodeoxycholic acid. The rate of degradation was somewhat decreased in an oxygen atmosphere, but the decrease was not statistically significant when the rate of degradation was compared with that of incubates in nitrogen. Since the incubates were not shaken during incubation, the degree of penetration of the gas into the medium was thought to be limited. When the mixtures were shaken in air during incubation, the effect was to slow down significantly the rate of degradation. The replacement of the medium by water had only a modest or no effect on the rate of conversion. The homogenized stool added to water in these experiments may have acted as its own medium.
The pH of the incubates varied from 5.39 to 6.55 before and from 5.75 to 6.61 at the end of the incubation procedures (24 hours). No attempts were made to standardize the pH, since the pH of the stool was thought to be an important characteristic of the environment of the intestinal bacteria. Under the present experimental conditions, the maximal rate of the conversion reaction was obtained over a pH range of 5 to 8.
Substrate-Enzyme Relationships.-By increasing the mass of stool added to the incubates, it was determined that maximal degradation occurred when the mass of the homogenate was equivalent to 100 mg dry weight of stool or more (in 24-hour incubates). Below this level the rate of degradation was markedly diminished (Fig. 2) . In 24 stool specimens (originating from six patients) simultaneous incubations were done with stools equivalent to 10, 25, 50, and 200 mg dry weight. An analysis of variance indicated that the four groups of weight were significantly different (P<0.05) from each other when the percents of radioactivity remaining at the spot corresponding to cholic acid were compared. When 10 mg of unlabeled cholate was added to the incubates, the rate of degradation was somewhat slowed down. In the 24-hour incubates, however, the 
Kinetic curves for the degradation of "'C-cholic acid (solid line) and its conversion to deaxijcholic acid (broken line) with the addition of increasing masses of stool homogenates in 24-hour incubations.
degradation of cholate was almost as complete as it was in incubates containing no unlabeled material. With increasing mass of substrate added to the incubates, the curve reached a plateau after the addition of 10 mg of sodium cholate, when the results were expressed as mass of cholate degraded (in mg) (Fig. 3) . With the addition of increasing masses of deoxycholic, chenodeoxycholic, and lithocholic acid to the incubates, the dihydroxy compounds had a somewhat less pronounced but essentially similar effect on cholate degradation as did the trihydroxy compound. The addition of lithocholic acid up to 100 mg/incubate had no visible influence on the degradation of cholate, presumably due to its insolubility. experiments the effect of the addition of increasing masses of autoclaved stool to the incubates (equivalent to 400-2000 mg dry weight) was studied. The incubates contained the equivalent of 200 mg of nonautoclaved feces. The addition of the autoclaved stool had no visible influence on the degradation process. These data indicate that normal stools do not contain a heat-stable inhibitor of the conversion reaction (such as bile acids) which is effective under the present experimental conditions.
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To explore this possibility further, the addition of 15 mg and 10 mg of unlabeled sodium cholate to the test systems with stool homogenates of patients treated with neomycin or kanamycin yielded identical results compared with those for routine incubates.
In another series of experiments the stool homogenates of two patients treated with neomycin and kanamycin were incubated with stool homogenates of untreated control subjects. The addition of feces from the antibiotic-treated patients to the test systems failed to inhibit the degradation of bile acids by the control stool sample. These experiments indicated that the stool homogenates of patients treated with neomycin or kanamycin did not contain an inhibitor of the degradation process. Therefore, the administration of the antibiotic interfered with or markedly decreased the growth of bile acid-degrading bacteria within the intestinal tract of patients.
Storage of Feces.-When the stool specimens were stored before incubation at room temperature for 24 hours or less, there was no perceptible change in the rate of degradation. After longer storage, the activity of the samples decreased. Refrigeration during storage further decreased the activity of the samples.
Results
The experimental medications were well tolerated by the patients, and no major side effects were encountered. Physical examinations and monitoring laboratory tests were unchanged.
The stools were routinely incubated for 2 hours and 24 hours. The results for 2 hours were qualitatively the same as the 24-hour results. During control periods, stool specimens of six normally converting patients were autoclaved before incubation, or ethanol was added to the medium before introduction of fecal homogenates. Under these conditions there was no degradation and an average of 94.5% of radioactivity was recovered from the spot corresponding to cholic acid.
Neomycin sulfate (2 g daily) was given orally to 13 patients for 2 weeks (Tables 1 and 2 ). In 11 patients the concentration of serum cholesterol decreased during the 2 weeks of neomycin administration. The overall average serum cholesterol level during control periods was 316 mg/100 ml plasma; during the administration of neomycin it fell to 237 mg/100 ml plasma. During control periods the average distribution of radioactivity on the thinlayer chromatography plates showed 5.7% of labeled material migrating to the spot corresponding to cholic acid and 88.6% migrating to that of deoxycholic acid. During the administration of neomycin, the degradation of cholic acid was markedly decreased or was practically absent in the fecal incubates of each of the 11 patients. An average of 77.9% of radioactivity migrated to the spots corresponding to cholic acid and only 9.0% to those corresponding to deoxycholic acid. In two patients, the administration of neomycin had no effect on serum cholesterol levels (average during control periods 452 mg/100 ml plasma, average during neomycin administration 440 mg/100 ml plasma), In these two patients the capability of the fecal bacterial flora to degrade cholic acid remained practically unchanged. Only an average of 5.9% of radioactivity remained at the spots corresponding to cholic acid during control periods, and 7.3% remained during the administration of neomycin. u C-Chenodeoxycholic acid was incubated with fecal homogenates in four patients ( Table 2 ). The degradation of chenodeoxycholic acid was essentially similar to that of cholic acid. During the administration of neomycin the conversion of chenodeoxycholate diminished markedly. Kanamycin sulfate (2 g daily) was given orally to eight patients (Table 3 ). In five patients the administration of the drug reduced the level of serum cholesterol from an average of 280 mg/100 ml plasma to 252 mg/100 ml plasma. In these patients the in vitro degradation of cholic acid was markedly inhibited. In three additional patients the administration of kanamycin failed to alter serum cholesterol levels. The rate of conversion of cholic acid remained virtually unchanged in these subjects during the administration of the drug.
Chloramphenicol (2 g daily) was given to three patients (Table 3) . Although this antibiotic had no effect on serum cholesterol levels in previous studies (3), in two of the three patients a moderate but significant reduction in serum cholesterol levels occurred. In these patients, the rate of conversion of cholic acid was also moderately but significantly decreased. In the third subject there was no change in serum cholesterol concentrations, and the rate of conversion of cholic acid remained unchanged. Table 3 shows the results obtained during the oral administration of chlortetracycline (1.5 g daily). In three patients, the level of serum cholesterol decreased significantly during the administration of the drug. The rate of degradation of cholic acid also decreased, although the change was much less pronounced than that with the administration of neomycin. In an additional patient, the level of serum cholesterol decreased markedly without a change in the rate of conversion. Tetracycline (1.5 g), streptomycin (2 g), ampicillin (2 g), and sulfisoxazole (3 g) were each given orally to different patients daily (Table 3 ). These drugs had no effect on serum cholesterol level, and the rate of degradation of cholic acid remained unchanged during their administration.
The percent of radioactivity remaining at the spot corresponding to cholic acid after incubation was plotted against the percent decrease in serum cholesterol concentrations. The correlation coefficient was calculated on the results of 31 experiments, including each experiment with cholic acid incubations (Tables 1-3) except that for patient no. 23 (Table 3) whose results showed the only exception encountered in this study. The calculated correlation coefficient (r = 0.732) was statistically significant ( P < 0.001).
Three of 13 patients developed mild temporary diarrhea during the administration of neomycin; the remaining 8 patients had normal bowel movements. There was no visible difference in serum cholesterol reduction or bile acid degradation between symptomatic and asymptomatic patients. During the administration of kanamycin 2 patients developed diarrhea, 1 was a responder and 1 was a nonresponder. The administration of tetracycline and ampicillin induced increased bowel motility but had no effect on serum cholesterol levels or on bile acid degradation. Meihoff and Kern (20) demonstrated that mannitol-induced diarrhea resulted in mild steatorrhea and in only a slight increase in fecal bile acid excretion. These data suggest that the changes reported in the present study were not due to increased bowel motility but were probably due to the antibacterial action of the drugs used.
Concerning drug adherence, each of the patients in this study was well known to us. Many had participated in previous studies and were highly reliable. A pill count was taken at each visit to the clinic. All patients came to the clinic twice weekly, brought fresh stool specimens, and at each visit had a venipuncture to draw blood, In 16 of the 36 experimental series there was no response to the medication (cholesterol reduction 10% or less). It is highly unlikely that this many of the patients Circulation Research, Vol. XXXIII, October 1973 selected for this study (44%) failed to adhere to their drug schedule.
Of the 25 patients participating in this study, 9 had scrum lipid levels regarded as normal, 12 had hypercholesterolemia (type II lipoprotein pattern), and 4 had hypertriglyceridemia (type IV lipoprotein pattern) (Tables 1-3) (21) . On examination of these data, the response to the experimental medications had no apparent relationship to the initial serum lipid levels or to the type of hyperlipoproteinemia of the patient.
Discussion
The data indicate that the administration of antibiotics that reduced the level of serum cholesterol in man also markedly inhibited the degradation of primary bile acids by the fecal bacterial flora. Conversely, the patients in whom degradation of bile acids was not visibly affected during the administration of neomycin, kanamycin, or chloramphenicol, failed to show a decrease of serum cholesterol concentrations. Other antibacterial drugs that had no effect on serum cholesterol levels had no influence on the degradation of cholic acid. Although these data suggest more than a coincidental relationship, it must be emphasized that the present results cannot be interpreted as proving a direct cause-effect function between serum cholesterol levels, the prevalence of bile acid-degrading bacteria in the intestinal flora, and the mechanism of the cholesterol-lowering action of the antibiotics in question. There is, however, very little in common in the chemical structure or characteristics of the neomycin-kanamycin group of antibiotics, chloramphenicol, and chlortetracycline. Thus, the only common denominator between these antibiotics is that they lowered human serum cholesterol levels and interfered with the action of bile acid-degrading bacteria of the normal intestinal flora, Other broad-spectrum antibiotics such as tetracycline, streptomycin, or ampicillin, with no effect on serum cholesterol levels, had no apparent influence on bile acid-degrading bacteria.
Bacterial Enzymes and Bile
Adds.-The present data indicate that bile acids were degraded by a component in feces that was destroyed or inactivated by heat and ethanol. Although a heat-or ethanol-labile enzyme originating, for example, from the intestinal tract could theoretically be responsible for the changes, it was assumed that the observed conversion was due to bacterial action. Large numbers of intestinal bacteria have been reported to degrade bile acids in vitro. The bacterial enzymes most studied were cholanoyl hydrolase (22, 23) which deeonjugates bile salts by splitting the peptide bond, hydroxycholanoyl dehydrogenase (24, 25) which dehydrogenates the 3a-, 7a-and 12a-hydroxyl groups, and hydroxycholanoyl dehydroxylase (23, (26) (27) (28) which removes the 7a-hydroxyl groups and thus transforms cholic (3a-7a-12a-trihydroxy) into deoxycholic (3a-12a-dihydroxy) acid and chenodeoxycholic (3a-7a-dihydroxy) into lithocholic (3a-monohydroxy) acid. The end result of the action of intestinal bacteria on the bulk of the two primary bile acids synthesized by the liver (conjugated cholic and chenodeoxycholic) is their transformation into free 7a-dehydroxylated forms. Thus, normal human feces contain mostly deoxycholic and lithocholic acids together with small amounts of other cholanic acids resulting from bacterial action.
The objectives of the present study were not the isolation and qualitative and quantitative determination of 7a-dehydroxylating bacteria in pure culture. The method was designed uniquely to test the degrading capability of whole fecal homogenates of primary bile acids. Thus, the number or kind of anaerobic organisms growing under the present experimental conditions was not tested, and the surviving strains of anaerobes in our culture media remained unknown.
Incubation Procedure.-The addition of 10 mg of cholate to the incubates slowed somewhat the rate of degradation of labeled cholic acid. Since the administration of neomycin may increase the bile acid content of feces (9, 10) , it was decided that the experiments would be carried out without the addition of unlabeled substrate to the incubates. The procedure was thought to be sufficiently standardized so that comparable and reproducible results could be obtained without the introduction of additional substrate into the incubates. On the other hand, it was clearly shown that under the present experimental conditions the absence of bile acid degradation during the administration of antibacterial drugs was not due to the presence of an inhibitory substance in feces. When fecal homogenates of a normally converting subject were added to the stools of patients treated with neomycin or kanamycin, the degradation of cholic acid proceeded without inhibition. Furthermore, in experiments with neomycin, the incubation of very small amounts of stool homogenates equivalent to 10, 25, and 50 mg of dry stool mass yielded essentially identical results compared with routinely used stool masses. These small masses could not have contained sufficient amounts of trihydroxy or dihydroxy bile acids to exert any inhibitory effect on the degradation of the added labeled cholic acid (Fig. 3) .
The results of the administration of chlortetracycline showed rather large variations and sometimes erratic individual changes. In one patient, serum cholesterol levels decreased without a change in bile acid degradation (Table 3 ). This case was (he only exception to the rule encountered in this study.
Possible Mechanisms.-If we assume that the findings in the present study are more than coincidental, then several possible explanations can be suggested. First, it is conceivable that the prevalence of trihydroxy over dihydroxy bile acids within the lumen of the gastrointestinal tract might influence the rate of cholesterol absorption. Second, the rate of biosynthesis of cholesterol by the intestinal mucosa might be different in the presence or the absence of deoxycholate. Third, the effects described might be due to differential rates of absorption of bile acids by the intestine. Considering the sum total of active and passive transport mechanisms in the absorption of bile acid from the gastrointestinal tube (29, 30) , whether secondary bile acids are reabsorbed faster than the primary compounds during the entire passage from the duodenum to the rectum has not been proved. If the rate of reabsorption of deoxycholate is faster than that of cholate, then increased bacterial formation of deoxycholate in the human intestines may result in increased portal return of bile acids to the liver. If the growth or activity of 7a-dehydroxylating bacteria were inhibited, the fecal excretion of bile acids would increase. The amount and kind of bile acids returning to the liver may also inhibit hepatic cholesterol biosynthesis to varying degrees. At present, however, there is no direct evidence that any of these mechanisms are operative.
It is suggested that the prevalence of 7a-dehydroxylase-producing bacteria within the gastrointestinal tract, and thus the ratio of trihydroxy to dihydroxy bile acids might be under the control of environmental factors. Therefore, the prevalence of a single enzyme within the gastrointestinal tract, 7a-dehydroxyla.se, or maybe a group of bile acid-degrading enzymes produced by certain intestinal bacteria could possibly be responsible in part for the environmentally induced shifts in the increases or decreases of body pools of cholesterol. It is possible that the rapid rise of serum cholesterol level of the newborn, for example, may be due to colonization by 7a-dehydroxylase-producing bacteria (31) .
Pertinent Animal Studies.-The oral administration of neomycin to rats and rabbits yielded results exactly opposite to those observed in man. In the cholesterol-fed rabbit (32) and in the cholcsterolcholate-fed rat (33) , the administration of neomycin significantly increased the level of plasma cholesterol. Fecal excretion of bile acids in the neomycinfed rat was significantly decreased (34) . This finding, incidentally, suggests that the action of the drug cannot be explained merely on the basis of the precipitation of micellar solutions by neomycin (11, 13, 16) . In conventional and germ-free chicks the administration of neomycin induced diarrhea and malabsorption and reduced body weight gain with concomitant reduction of serum and liver cholesterol (35) . In germ-free pigs the level of plasma cholesterol did not change during neomycin administration (36) . In germ-free rats, the fecal excretion of bile acids (and neutral steroids) was about onehalf of that of conventional rats (37) , and fecal bile acids consisted mostly of undegraded compounds. The rate of turnover of bile acid pools was decreased in the germ-free rat (38) . The administration of neomycin to germ-free rats had no effect on plasma cholesterol levels or fecal bile acid excretion (34) , showing that in this species the effect of the drug depended on its action on the intestinal bacterial flora. In a review article, Kellogg (39) concluded that the intestinal microflora protected experimental animals against increased plasma and tissue cholesterol leveLs. While this phenomenon is undoubtedly true in the rat, in man certain elements of the intestinal microflora seem to act in the opposite direction. The reasons for this discrepancy are not apparent. Whether the difference in the composition of the circulating bile acid pools, possible differences in sterol absorption, or the presence of a 7a-hydroxylating enzyme in rat liver (absent in man) may partly participate in this remarkable species difference between man and rat is not clear at present.
